Open Access

Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines

  • Authors:
    • Suyanee Thongchot
    • Pranisa Jamjuntra
    • Jaturawitt Prasopsiri
    • Peti Thuwajit
    • Nunghathai Sawasdee
    • Naravat Poungvarin
    • Malee Warnnissorn
    • Doonyapat Sa‑Nguanraksa
    • Pornchai O‑Charoenrat
    • Pa-Thai Yenchitsomanus
    • Chanitra Thuwajit
  • View Affiliations

  • Published online on: October 15, 2021     https://doi.org/10.3892/or.2021.8205
  • Article Number: 254
  • Copyright: © Thongchot et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer cell lines are widely used as an in vitro system with which to study the mechanisms underlying biological and chemotherapeutic resistance. In the present study, two novel breast cancer cell lines designated as PC‑B‑142CA and PC‑B‑148CA were successfully established from HER2‑positive and triple‑negative (TN) breast cancer tissues. The cell lines were characterized by cytokeratin (CK), α‑smooth muscle actin (α‑SMA), fibroblast‑activation protein (FAP) and programmed death‑ligand 1 (PD‑L1). Cell proliferation was assessed using a colony formation assay, an MTS assay, 3‑dimensional (3‑D) spheroid and 3‑D organoid models. Wound healing and Transwell migration assays were used to explore the cell migration capability. The responses to doxorubicin (DOX) and paclitaxel (PTX) were evaluated by 3‑D spheroids. The results showed that the PC‑B‑142CA and PC‑B‑148CA cell lines were α‑SMA‑negative, FAP‑negative, CK‑positive and PD‑L1‑positive. Both cell lines were adherent with the ability of 3‑D‑multicellular spheroid and organoid formations; invadopodia were found in the spheroids/organoids of only PC‑B‑148CA. PC‑B‑142CA had a faster proliferative but lower metastatic rate compared to PC‑B‑148CA. Compared to MDA‑MB‑231, a commercial TN breast cancer cell line, PC‑B‑148CA had a similar CD44+/CD24 stemness property (96.90%), whereas only 8.75% were found in PC‑B‑142CA. The mutations of BRCA1/2, KIT, PIK3CA, SMAD4, and TP53 were found in PC‑B‑142CA cells related to the resistance of several drugs, whereas PC‑B‑148CA had mutated BRCA2, NRAS and TP53. In conclusion, PC‑B‑142CA can serve as a novel HER2‑positive breast cancer cell line for drug resistance studies; while PC‑B‑148CA is a novel TN breast cancer cell line suitable for metastatic and stemness‑related properties.
View Figures
View References

Related Articles

Journal Cover

December-2021
Volume 46 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Thongchot S, Jamjuntra P, Prasopsiri J, Thuwajit P, Sawasdee N, Poungvarin N, Warnnissorn M, Sa‑Nguanraksa D, O‑Charoenrat P, Yenchitsomanus P, Yenchitsomanus P, et al: Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines. Oncol Rep 46: 254, 2021
APA
Thongchot, S., Jamjuntra, P., Prasopsiri, J., Thuwajit, P., Sawasdee, N., Poungvarin, N. ... Thuwajit, C. (2021). Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines. Oncology Reports, 46, 254. https://doi.org/10.3892/or.2021.8205
MLA
Thongchot, S., Jamjuntra, P., Prasopsiri, J., Thuwajit, P., Sawasdee, N., Poungvarin, N., Warnnissorn, M., Sa‑Nguanraksa, D., O‑Charoenrat, P., Yenchitsomanus, P., Thuwajit, C."Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines". Oncology Reports 46.6 (2021): 254.
Chicago
Thongchot, S., Jamjuntra, P., Prasopsiri, J., Thuwajit, P., Sawasdee, N., Poungvarin, N., Warnnissorn, M., Sa‑Nguanraksa, D., O‑Charoenrat, P., Yenchitsomanus, P., Thuwajit, C."Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines". Oncology Reports 46, no. 6 (2021): 254. https://doi.org/10.3892/or.2021.8205